Salt forms and polymorphs of (r)-1-(4-(6-(2-(4-(3,3-difluorocyclobutoxy)-6-methylpyridin-2-yl)acetamido) pyridazin-3-yl)-2-fluorobutyl)-n-methyl-1H-1,2,3-triazole-4-carboxamide

US11603365B2 · kind B2 · utility

Assignee

• The Board of Regents of the University of Texas System · US

Inventors

• Philip Jones · Houston, US
• Michael Soth · Glen Rock, US
• Jason P. Burke · Houston, US
• Kang Le · Sugar Land, US
• Gang Liu · Sugar Land, US

Key dates

• Filing date: Dec 16, 2020
• Grant date: Mar 14, 2023
• Expiry date: May 27, 2041

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07B2200/13
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Disclosed herein is the compound (R)-1-(4-(6-(2-(4-(3,3-difluorocyclobutoxy)-6-methylpyridin-2-yl)acetamido) pyridazin-3-yl)-2-fluorobutyl)-N-methyl-1H-1,2,3-triazole-4-carboxamide, and salt forms and polymorphs thereof demonstrating improved exposure after oral dosing. Methods of inhibition GLS1 activity in a human or animal subject are also provided.